Pacific Biosciences CCO Peter Fromen resigns effective May 20, 2022

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Peter Fromen resigns as Chief Commercial Officer to pursue new opportunities, effective May 20, 2022.
Departure not due to any disagreement with company operations, policies, or practices.
CEO Christian Henry assumes marketing responsibilities; VP Chris Seipert takes over sales, service, and support.
Company conducting a search for a permanent Chief Commercial Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Fromen

Chief Commercial Officer

PACB · PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Effective: 2022-05-20
Filed: May 17, 2022, 7:59 PM ET

On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his intention to resign, effective as of May 20, 2022, to pursue new opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Peter Fromen resigned as Chief Commercial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On May 14, 2022, Peter Fromen, the Chief Commercial Officer of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his intention to resign, effective as of May 20, 2022, to pursue new opportunities.

View on SEC.gov

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-061927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.